Prevention and mitigation of LV dysfunction

16 Aug 2021

Prof. Anita Arnold

Prof. Peter Van der Meer , FESC

Profs. Anita Arnold, Florida State University, USA and Peter Van Der Meer, University Medical Center Groningen, The Netherlands, discuss the prevention and mitigation of LV dysfunction in patients receiving cardiotoxic cancer therapy.

Publications cited during the Talk

• Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry
• Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies
• Evaluation and management of patients with heart disease and cancer: cardio-oncology
• Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.